


**Westminster Health Forum Keynote Seminar**  
**Next steps for antimicrobials and combating antimicrobial resistance:**  
**funding, research and clinical practice**

Timing: Morning, Thursday, 6<sup>th</sup> July 2017

Venue: Glaziers Hall, 9 Montague Close, London SE1 9DD

Agenda subject to change



**WESTMINSTER  
HEALTH FORUM**

- 8.30 - 9.00 Registration and coffee
- 9.00 - 9.10 **Chair's opening remarks and lessons from the O'Neill Review**  
**Lord O'Neill of Gatley**, Chair, Review on Antimicrobial Resistance
- 9.10 - 9.30 **Assessing the scale of antimicrobial resistance and improving awareness**  
**Professor Alan Johnson**, Head, Department of HCAI and AMR National Infection Service, Public Health England  
Questions and comments from the floor
- 9.30 - 10.30 **Key issues for funding and developing new antimicrobials**  
*How should the UK Government target its financial contribution to tackle AMR, and what impact has the AMR Innovation Fund had on resistance in the international context? What impact will the UK leaving the European Union have on that response? What measures, for example, systems of market entry rewards or steps to address underlying market disincentives, would best improve the financial incentive for industry to develop new antimicrobials? What impact will efforts to streamline regulation and appraisal, for example through measures recommended in the Accelerated Access Review, improve the financial case for developing new antimicrobials? What measures can be taken to improve the capacity for further research into AMR, and to what extent has investment through the Fleming and Newton Funds addressed this? What more can be done to prioritise development into new antimicrobials that treat infections which are currently completely resistant to all available antibiotics?*  
**James Anderson**, Chair, Antibiotic Network, ABPI and Head of Corporate Government Affairs, GSK
- Dr Michael Adeogun**, Strategy Head, Life Sciences and Health, National Physical Laboratory
- Professor Laura Bowater**, Professor of Microbiology Education and Engagement, University of East Anglia
- Professor Hilary Thomas**, Chief Medical Adviser and Member,  
Centre of Excellence in Healthcare and Life Sciences, KPMG
- Questions and comments from the floor
- 10.30 - 11.15 **Priorities for tackling antimicrobial resistance and next steps for policy**  
**Professor Dame Sally Davies**, Chief Medical Officer, Department of Health  
Questions and comments from the floor
- 11.15 - 11.20 **Chair's closing remarks**  
**Lord O'Neill of Gatley**, Chair, Review on Antimicrobial Resistance
- 11.20 - 11.50 Coffee
- 11.50 - 11.55 **Chair's opening remarks**  
**Professor Alan Johnson**, Head, Department of HCAI and AMR National Infection Service, Public Health England
- 11.55 - 12.05 **Case study: lessons and priorities for reducing antibiotic prescribing from Oldham**  
**Dr Anita Sharma**, GP and Clinical Director (Vascular), NHS Oldham Clinical Commissioning Group and GP Member, NICE Quality Standard Advisory Committee
- 12.05 - 12.55 **Challenges for antimicrobial stewardship: diagnosis, prescribing and preventing Gram-negative infections**  
*In light of Public Health England's latest 'English surveillance programme for antimicrobial utilisation and resistance' (ESPAUR) report, which highlighted that although some improvements had been made in antimicrobial stewardship more work was needed, what further measures should be put in place, particularly by community health trusts, to improve the NHS response to AMR? Since the introduction of the AMR CQUIN, as part of the NHS Standard Contract, what has been the impact of financial incentives to improve antimicrobial stewardship and reduce unnecessary prescribing? What more should be done to improve the NHS' diagnostics capacity following the Government response to Lord O'Neill's AMR Review highlighting the importance of access to cost-effective and rapid diagnostics? With a response to AMR stressing a 'One Health' approach, how could health organisations improve collaboration with the animal health sector in order to tackle AMR, and how can the Government improve surveillance across both areas?*  
**Dr Suzy Lishman**, President, Royal College of Pathologists and Consultant Histopathologist, Peterborough and Stamford Hospitals NHS Foundation Trust  
**Daniel White**, Executive Regional Director, Cepheid and Chair, AMR Working Party, BIVDA  
**Paul Wade**, Member, Antimicrobial Resistance Expert Advisory Group, Royal Pharmaceutical Society and Consultant Pharmacist, Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust  
**Sean Wensley**, Senior Vice President, British Veterinary Association  
Questions and comments from the floor with **Dr Anita Sharma**, GP and Clinical Director (Vascular), NHS Oldham Clinical Commissioning Group and GP Member, NICE Quality Standard Advisory Committee
- 12.55 - 13.00 **Chair's and Westminster Health Forum closing remarks**  
**Professor Alan Johnson**, Head, Department of HCAI and AMR National Infection Service, Public Health England  
**Sam Dolton**, Senior Producer, Westminster Health Forum